Last reviewed · How we verify

dacomitnib — Competitive Intelligence Brief

dacomitnib (dacomitnib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis. Area: Oncology.

discontinued patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis Oncology Live · refreshed every 30 min

Target snapshot

dacomitnib — Pfizer Inc.. patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
dacomitnib TARGET dacomitnib Pfizer Inc. discontinued patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dacomitnib — Competitive Intelligence Brief. https://druglandscape.com/ci/dacomitnib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: